FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to medicine and deals with stable composition for provision of subject with therapeutically or prophylactically effective amount of alpha-1 protease inhibitor (API), containing alpha-1 protease inhibitor (API) and at least one amino acid, selected from alanine, threonine, serine or hydroxyproline, where said composition includes one or more auxiliary substances, where at least one amino acid is present in composition in the total amount of amino acid from approximately 0.01 M to approximately 3 M. Group of inventions also deals with set for treatment or prevention of API-associated disease or condition, which includes said composition; application of at least one amino acid, selected from alanine, threonine, serine or hydroxyproline, for stabilisation of composition, containing alpha-1 protease inhibitor (API).
EFFECT: group of inventions provides stability of API composition.
15 cl, 27 dwg, 5 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING PLASMINOGEN, AND USE THEREOF | 2015 |
|
RU2711989C2 |
| COMPOSITIONS BASED ON BISPECIFIC ANTIBODIES TO IL-4/IL-13 | 2014 |
|
RU2690850C2 |
| COMPOSITION OF NEUREGULIN PREPARATION | 2014 |
|
RU2738158C2 |
| ANTIBODY COMPOSITION | 2015 |
|
RU2743681C2 |
| STABLE AQUEOUS COMPOSITIONS OF PROTEIN MIA/CD-RAP | 2011 |
|
RU2588658C2 |
| FORMULATIONS WITH ADENO-ASSOCIATED VIRUS | 2017 |
|
RU2769196C2 |
| LIQUID COMPOSITION OF POLYPEPTIDES CONTAINING FC DOMAIN OF IMMUNOGLOBULIN | 2011 |
|
RU2600847C2 |
| NEW ALBUMIN-FREE COMPOSITIONS OF FACTOR VIII | 2000 |
|
RU2244556C2 |
| COMPOSITIONS CONTAINING ANTIBODY-DRUG CONJUGATES DUOCARMICIN | 2016 |
|
RU2687237C1 |
| STABLE PHARMACEUTICAL COMPOSITION OF TNFR: FC FUSION PROTEIN | 2013 |
|
RU2664691C2 |
